FDA Authorizes Modified Risk Claims for ZYN Nicotine Pouches: A Landmark Step for Tobacco Harm Reduction

Short summary

The FDA authorized Swedish Match USA to market ZYN nicotine pouches with modified-risk claims, stating they reduce risk of smoking-related diseases compared to cigarettes. This is the first reduced-risk authorization under the 2009 Tobacco Control Act's MRTP pathway, covering 20 products in various flavors and nicotine strengths. The approval requires five-year postmarket surveillance and population-health impact monitoring.

• •FDA authorized ZYN nicotine pouches for reduced-risk claims versus cigarettes
• •First reduced-risk (not exposure-only) authorization under 2009 MRTP pathway
• •Covers 20 products; requires five-year postmarket surveillance and population-health review

Generated with AI, which can make mistakes.